Observational studyInternational journal of clinical pharmacy2017
Development of a risk score for QTc-prolongation: the RISQ-PATH study.
Observational study in International journal of clinical pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02068170 (Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review.European journal of clinical pharmacology · 2022Pooled it
- Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Pooled it
- Risk for QTc prolongation in patients of various medical specialties - a retrospective study on risk factors and usability of the Tisdale Score.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Assessing the risk of drug-induced corrected QT interval prolongation in primary care.Family practice · 2026Article
- QT Prolongation and Arrhythmias in Cancer Therapy: A Narrative Review of Mechanistic and Clinical Studies.Cardiovascular toxicology · 2026Review
- [Drug interactions in uro-oncology].Urologie (Heidelberg, Germany) · 2026Review
- Tisdale-score-based risk stratification of QTc prolongations in hospitalized patients receiving azole antifungal therapy-a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- Prevalence of the QT interval prolongation and its risk factors in hospitalized geriatric patients: findings of a single center cross-sectional study in Pakistan.BMC geriatrics · 2025Article
- Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?BMC medical informatics and decision making · 2025Article
- Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients.Pharmacology research & perspectives · 2025Observational
- Risk Stratification of QTc Prolongations in Hospitalized Cardiology and Gastroenterology Patients Using the Tisdale Score-A Retrospective Analysis.Journal of clinical medicine · 2025Article
- Pharmacist-assisted implementation of guideline recommendations for QTc monitoring during psychopharmacotherapy - a prospective, randomized feasibility study.Frontiers in psychiatry · 2025Article
- Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study.International journal of clinical pharmacy · 2024Article
- QTc Interval Prolongation as an Adverse Event of Azole Antifungal Drugs: Case Report and Literature Review.Microorganisms · 2024Review
- Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer.Journal of pharmaceutical health care and sciences · 2024Article
- A quality improvement study of the implementation and initial results of a pragmatic clinical decision support system in the community pharmacy setting.International journal of clinical pharmacy · 2024Observational
- QTc prolongation risk among patients receiving oral targeted antineoplastic medications: A real-world community-based oncology analysis.Frontiers in oncology · 2023Article
- Prolonged QT Interval in Cirrhosis: Twisting Time?Gut and liver · 2022Review
- Is the association of QTc with atrial fibrillation and stroke in cohort studies a matter of time?Open heart · 2022Article
- Study of the indications for macrolide prescriptions in a Colombian populationBiomedica : revista del Instituto Nacional de Salud · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background More than 170 drugs are linked with QTc-prolongation, which in extreme cases can lead to Torsade de Pointes. Monitoring of this potential side effect is an important challenge in clinical practice. Objective To investigate the risk of QTc-prolongation in hospital patients who started a QTc-prolonging drug, and to develop a risk score to identify patients at high/low risk for QTc-prolongation. Setting University Hospitals Leuven, Belgium. Method All patients starting with haloperidol or a QTc-prolonging antibiotic/antimycotic were eligible for this observational study. Twelve-lead electrocardiograms were recorded at baseline and follow-up (steady state). Demographic, medical and drug data were collected. The obtained data were used to calculate the performance characteristics of a preliminary risk score (RISQ-PATH score), based on a systematic review of risk factors. ROC analysis determined a score of <10 points as a low risk for QTc-prolongation. Main outcome measure QTc-interval in a baseline and follow-up electrocardiogram. Results 178 patients (46.6% female; mean age 69 ± 14 years) were included (levofloxacin: N = 80; haloperidol: N = 41; fluconazole: N = 41). Overall, no significant difference between the mean QTc-values at baseline (425.7 ± 31.7 ms) and follow-up (428.0 ± 30.7 ms) was found (p = 0.328). However, 26 patients (14.6%) did develop a prolonged QTc-interval (≥450(♂)/470(♀) ms) of whom 25 with a RISQ-PATH score ≥10. This score had a sensitivity of 96.2% (95% CI 78.4-99.8%) and a negative predictive value of 98.0% (95% CI 88.2-99.9%). Conclusion This RISQ-PATH score is able to rule out low-risk patients with a negative predictive value of 98.0% and is promising to exclude patients from further follow-up when starting QTc-prolonging drugs. Clinicaltrials.gov Registration Number: NCT02068170.
Indexed as
Identifiers
28281228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.